Cargando…

Oncogene-Addicted Non-Small-Cell Lung Cancer: Treatment Opportunities and Future Perspectives

Before the introduction of tyrosine kinase inhibitors (TKIs) for a particular subgroup of patients, despite platinum-based combination chemotherapy, the majority of patients affected by non-small-cell lung cancer (NSCLC) did not live longer than one year. With deeper understanding of tumor molecular...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ferrara, Miriam Grazia, Di Noia, Vincenzo, D’Argento, Ettore, Vita, Emanuele, Damiano, Paola, Cannella, Antonella, Ribelli, Marta, Pilotto, Sara, Milella, Michele, Tortora, Giampaolo, Bria, Emilio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281569/ https://www.ncbi.nlm.nih.gov/pubmed/32397295 http://dx.doi.org/10.3390/cancers12051196

Ejemplares similares

Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory “FoRECATT” study
por: Di Noia, Vincenzo, et al.
Publicado: (2020)

Long-term survivors with immunotherapy in advanced NSCLC: is ‘cure’ within reach?
por: Monteverdi, Sara, et al.
Publicado: (2020)

Lung and Gut Microbiota as Potential Hidden Driver of Immunotherapy Efficacy in Lung Cancer
por: Carbone, Carmine, et al.
Publicado: (2019)

The Renaissance of KRAS Targeting in Advanced Non-Small-Cell Lung Cancer: New Opportunities Following Old Failures
por: Ferrara, Miriam Grazia, et al.
Publicado: (2021)

Large Cell Neuro-Endocrine Carcinoma of the Lung: Current Treatment Options and Potential Future Opportunities
por: Ferrara, Miriam Grazia, et al.
Publicado: (2021)

Unweaving the mitotic spindle: A focus on Aurora kinase inhibitors in lung cancer
por: Stefani, Alessio, et al.
Publicado: (2022)

Collagenous colitis and atezolizumab therapy: an atypical case
por: Gallo, Antonella, et al.
Publicado: (2020)

Clinical Stage III NSCLC Patients Treated with Neoadjuvant Therapy and Surgery: The Prognostic Role of Nodal Characteristics †
por: Chiappetta, Marco, et al.
Publicado: (2022)

Adjuvant chemotherapy for resected non-small-cell lung cancer: future perspectives for clinical research
por: Bonomi, Maria, et al.
Publicado: (2011)

Revising PTEN in the Era of Immunotherapy: New Perspectives for an Old Story
por: Piro, Geny, et al.
Publicado: (2019)

Neoadjuvant treatment: A window of opportunity for nutritional prehabilitation in patients with pancreatic ductal adenocarcinoma
por: Trestini, Ilaria, et al.
Publicado: (2021)

Are TKIs favourable for the elderly with non-small-cell lung cancer?
por: Rossi, Sabrina, et al.
Publicado: (2016)

Treating disease progression with osimertinib in EGFR-mutated non-small-cell lung cancer: novel targeted agents and combination strategies
por: Di Noia, V., et al.
Publicado: (2021)

Oncological Frontiers in the Treatment of Malignant Pleural Mesothelioma
por: Vita, Emanuele, et al.
Publicado: (2021)

A narrative review on tumor microenvironment in oligometastatic and oligoprogressive non-small cell lung cancer: a lot remains to be done
por: Belluomini, Lorenzo, et al.
Publicado: (2021)

PTEN in Lung Cancer: Dealing with the Problem, Building on New Knowledge and Turning the Game Around
por: Gkountakos, Anastasios, et al.
Publicado: (2019)

Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers
por: Carbognin, Luisa, et al.
Publicado: (2015)

The Therapeutic Challenge of Disseminated Bone Marrow Metastasis From HR-Positive HER2-Negative Breast Cancer: Case Report and Review of the Literature
por: Garufi, Giovanna, et al.
Publicado: (2021)

Pancreatic Enzyme Replacement Therapy in Patients Undergoing First-Line Gemcitabine Plus nab-paclitaxel for Advanced Pancreatic Adenocarcinoma
por: Trestini, Ilaria, et al.
Publicado: (2021)

Smoking habit and hospitalization for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related pneumonia: The unsolved paradox behind the evidence.
por: Garufi, Giovanna, et al.
Publicado: (2020)

Evaluation of nutritional status in non-small-cell lung cancer: screening, assessment and correlation with treatment outcome
por: Trestini, Ilaria, et al.
Publicado: (2020)

Clinical, Pathological and Prognostic Features of Rare BRAF Mutations in Metastatic Colorectal Cancer (mCRC): A Bi-Institutional Retrospective Analysis (REBUS Study)
por: Calegari, Maria Alessandra, et al.
Publicado: (2021)

Masaoka-Koga and TNM Staging System in Thymic Epithelial Tumors: Prognostic Comparison and the Role of the Number of Involved Structures
por: Chiappetta, Marco, et al.
Publicado: (2021)

Anticipating EGFR Targeting in Early Stages of Lung Cancer: Leave No Stone Unturned
por: Belluomini, Lorenzo, et al.
Publicado: (2021)

Leptin-mediated meta-inflammation may provide survival benefit in patients receiving maintenance immunotherapy for extensive-stage small cell lung cancer (ES-SCLC)
por: Vita, Emanuele, et al.
Publicado: (2023)

mTOR Cross-Talk in Cancer and Potential for Combination Therapy
por: Conciatori, Fabiana, et al.
Publicado: (2018)

Role of mTOR Signaling in Tumor Microenvironment: An Overview
por: Conciatori, Fabiana, et al.
Publicado: (2018)

Identification of Targetable Liabilities in the Dynamic Metabolic Profile of EGFR-Mutant Lung Adenocarcinoma: Thinking beyond Genomics for Overcoming EGFR TKI Resistance
por: Gkountakos, Anastasios, et al.
Publicado: (2022)

Efficacy of topical beta-blockers in the management of EGFR-inhibitor induced paronychia and pyogenic granuloma-like lesions: case series and review of the literature
por: Sollena, Pietro, et al.
Publicado: (2019)

Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma
por: Bria, Emilio, et al.
Publicado: (2015)

The likelihood of being helped or harmed as a patient-centred tool to assess cyclin dependent kinase 4/6 inhibitors clinical impact and safety in metastatic breast cancer: a systematic review and sensitivity-analysis
por: Mastrantoni, Luca, et al.
Publicado: (2023)

Prognostic and predictive factors of eribulin efficacy in heavily pretreated patients affected by metastatic breast cancer: correlation with tumor biology and previous therapies
por: Rossi, Sabrina, et al.
Publicado: (2017)

Targeting of non-oncogene addiction
por: Igea, Ana, et al.
Publicado: (2015)

Physical Activity and Exercise in Lung Cancer Care: Will Promises Be Fulfilled?
por: Avancini, Alice, et al.
Publicado: (2019)

Development of a nomogram for predicting pathological complete response in luminal breast cancer patients following neoadjuvant chemotherapy
por: Garufi, Giovanna, et al.
Publicado: (2023)

Gastrointestinal Cancer Patient Nutritional Management: From Specific Needs to Novel Epigenetic Dietary Approaches
por: Cencioni, Chiara, et al.
Publicado: (2022)

Evidence-based tailored nutrition educational intervention improves adherence to dietary guidelines, anthropometric measures and serum metabolic biomarkers in early-stage breast cancer patients: A prospective interventional study
por: Trestini, Ilaria, et al.
Publicado: (2021)

Oncogenic mutation or overexpression of oncogenic KRAS or BRAF is not sufficient to confer oncogene addiction
por: Ito, Reina E., et al.
Publicado: (2021)

Oncogene addiction: resetting the safety switch?
por: Li, Yulin, et al.
Publicado: (2014)

BIM-mediated apoptosis and oncogene addiction
por: Li, Yulin, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_v6qf9drq0i3s75f8hfg4ps73qj